课题基金 / 基金详情

Mechanism of ligand : receptor complex assembly of platelet-derived growth factor (PDGF)

Mechanism of ligand : receptor complex assembly of platelet-derived growth factor (PDGF)
配体机制:血小板衍生生长因子(PDGF)受体复合物组装
批准号:
10680602
负责人:
MIYAZAWA Keiji
金额:
$1.86万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 1999

项目摘要

项目成果

MIYAZAWA Keiji的其他基金

相似基金

相关文献

中文摘要
翻译
血小板衍生生长因子是一种二聚体蛋白,通过酪氨酸激酶α和β受体发挥作用。重组α受体结构域1-4(αRd1-4)、1-3(αRd1-3)和1-2(αRd1-2)用于研究可溶性配体-受体复合体的组装。在微摩尔浓度下,αRd1-3和αRd1-4都形成了摩尔组成为1:2的复合体,即一个二聚体PDGF分子与两个可溶性受体结合。与αRd1-4相比,αRd1-3在配体过剩的条件下形成了可检测到的1:1络合物。在限制配体浓度的条件下,αRD1-4与αRD1-3相比,形成1:2络合物的能力增强。因此,我们得出结论,Ig-4介导的受体-受体相互作用稳定了该复合体。由于αrd1-4和αrd1-3在阻断亚纳摩尔浓度的血小板衍生生长因子与细胞表面受体的结合方面是相同的,我们还得出结论:…更多的这种作用主要是通过形成Ig样结构域4-独立的1:1配体-受体复合体来实现的。最后,由于αRd1-2以高亲和力结合PDGF1-BB,而PDGF1-AA仅以低亲和力结合,我们得出结论:α-受体的Ig-3含有对PDGFAA结合具有特殊重要性的表位,并且大多数与PDGF1-BB结合的表位位于Ig-1和2GST中。我们构建了αRd1-4和βRd1-3(αRd1-4-GST和βRd1-3-Gst)的重组GST融合蛋白,并对其阻断细胞表面受体的能力进行了分析。在α-和β-受体的情况下,与裂解形式相比,GST-融合蛋白的浓度需要低100-1,000倍。αRd1-4-Gst和βRd1-3-Gst与αRd1-4和βRd1-3相反,是以非配体二聚体形式存在的。与αRd1-4相比,共价交联的αRd1-4二聚体的效价提高了50倍。因此,我们得出结论,可溶性受体的二聚性是产生高拮抗效力的原因。较少
英文摘要
Platelet-derived growth factor (PDGF) is a dimeric protein that exerts its effects through tyrosine kinase α-and β-receptors. The extracellular part of each receptor is composed of five Ig-like domains.Recombinant α-receptor domains 1-4 (αRD1-4), 1-3 (αRD1-3), and 1-2 (αRD1-2) were prepared and used to study the assembly of soluble ligand-receptor complexes. With micromolar concentrations of PDGF, both αRD1-3 and αRD1-4 formed complexes of 1: 2 molar composition, i.e. one dimeric PDGF molecule bound two soluble receptors. αRD1-3, in contrast to αRD1-4, formed detectable 1:1 complexes under conditions of ligand excess. αRD1-4 displayed an increased ability to form 1:2 complexes as compared with αRD1-3 under conditions of limiting concentrations of ligand. We thus conclude that Ig-4-mediated receptor-receptor interactions stabilize the complex. Since αRD1-4 and αRD1-3 were equipotent in blocking binding of subnanomolar concentrations of PDGF to cell-surface receptors, we also conclude th … More at this effect is predominantly achieved through formation of Ig-like domain 4-independent 1:1 ligand-receptor complexes. Finally, since αRD1-2 bound PDGF-BB with high affinity, whereas PDGF-AA was bound only with low affinity, we conclude that Ig-3 of the PDGF α-receptor contains epitopes of particular importance for PDGF-AA binding and that most of the PDGF-BB-binding epitopes reside in Ig-1 and 2.Recombinant GST-fusion proteins of αRD1-4 andβRD1-3 (αRD1-4-GST and βRD1-3-GST) were generated and analyzed with regard to their ability to block PDGF binding to cell surface receptors. Both in the case of the α- and β-receptors, 100-1,000 fold lower concentration of the GST-fusion protein were required, as compared to the cleaved forms. αRD1-4-GST and βRD1-3-GST, in contrast to αRD1-4 and βRD1-3, were shown to occur as ligand independent dimers. Covalently cross-linked αRD1-4 dimers displayed a 50-fold increased potency as compared to αRD1-4. We thus conclude that the dimeric nature of the soluble receptors is responsible for the high antagonistic potency. Less
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
Leppanen O.-P.et al.: "Predimerization of recombinant platelet-derived growth factor extracellular domains increases antagonistic potency"Biochemistry. (印刷中). (2000)
Leppanen O.-P. 等人:“重组血小板衍生生长因子胞外结构域的预二聚化增加了拮抗效力”(出版中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Miyazawa, K., Wang, Y., Minoshima, S., Shimizu, N., and Kitamura, N.: "Structural organization and chromosomal localization of the human hepatocyte growth factor activator gene. Phylogenetic and functional relationship with blood coagulation factor XII, u
Miyazawa, K.、Wang, Y.、Minoshima, S.、Shimizu, N. 和 Kitamura, N.:“人肝细胞生长因子激活剂基因的结构组织和染色体定位。与凝血因子 XII 的系统发育和功能关系
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shimomura, T., Denda, K., Kawaguchi, T., T., Matusmoto, K., Miyazawa, K., and Kitamura, N.: "Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrance form"J. Biochem.. 126
Shimomura, T.、Denda, K.、Kawaguchi, T.、T.、Matusmoto, K.、Miyazawa, K. 和 Kitamura, N.:“多个蛋白水解位点释放可溶形式的肝细胞生长因子激活剂抑制剂
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Leppanen, O.-P, et al.: "Predimerization of rcombinant platelet-derived growth factor receptor extracellular domains increases antagonistic potency"Biochemistry. (印刷中). (2000)
Leppanen,O.-P 等人:“重组血小板衍生生长因子受体胞外结构域的预二聚化增加了拮抗效力”《生物化学》(出版中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 14 条
    Development of a method to detect heterogeneity of Smad transcriptional complexes
    • 批准号:
      17K19589
    • 项目类别:
      Grant-in-Aid for Challenging Research (Exploratory)
    • 资助金额:
      $4.16万
    • 财政年份:
      2017
    • 负责人:
      MIYAZAWA Keiji
    • 依托单位:
    Development of cell-response selective regulation of TGF-βsignaling
    • 批准号:
      22390052
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.98万
    • 财政年份:
      2010
    • 负责人:
      MIYAZAWA Keiji
    • 依托单位:
    Molecular basis of the signaling networks that regulate vasculogenesis
    • 批准号:
      17570106
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2005
    • 负责人:
      MIYAZAWA Keiji
    • 依托单位:
    Molecular mechanism of vascular endothelial/mural cell differentiation by receptor tyrosine kinases
    • 批准号:
      15570110
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.37万
    • 财政年份:
      2003
    • 负责人:
      MIYAZAWA Keiji
    • 依托单位:
    国内基金
    海外基金
    盐皮质激素受体抑制2型固有淋巴细胞活化加重心肌梗死后心室重构的作用机制
    • 批准号:
      82372202
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      侯旭敏
    • 依托单位:
    GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
    • 批准号:
      82371652
    • 项目类别:
      面上项目
    • 资助金额:
      45.00万元
    • 批准年份:
      2023
    • 负责人:
      刘开江
    • 依托单位:
    多囊卵巢综合征中甲酰肽受体2调控小胶质细胞代谢重编程导致GnRH神经元过度激活及HPO轴异常的病理机制研究
    • 批准号:
      82370797
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      陶弢
    • 依托单位:
    G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
    • 批准号:
      82370865
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      黄哲
    • 依托单位: